Evaluation of Neutrophil/Lymphocyte Ratio ,Platelet/Lymphocyte Ratio and CRP as Markers of Severity of Pre-eclampsia

NCT ID: NCT03630276

Last Updated: 2018-08-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

111 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-01

Study Completion Date

2018-08-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP as markers of severity of Pre-eclampsia

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Neutrophil/lymphocyte ratio

Group Type OTHER

Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP

Intervention Type DIAGNOSTIC_TEST

Lab

Platelet/lymphocyte ratio

Group Type OTHER

Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP

Intervention Type DIAGNOSTIC_TEST

Lab

CRP

Group Type OTHER

Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP

Intervention Type DIAGNOSTIC_TEST

Lab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP

Lab

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- PREECLAMPSIA from 25\_45years

Exclusion Criteria

* chronic diseases Primary hypertension
Minimum Eligible Age

25 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Shaza Mohamed Elreweny

Shaza Mohamed Elreweny

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Shaza

Alexandria, Alex, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Shaza Mohamed Elreweny, Master

Role: primary

01090700297

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Shaza Elreweny

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.